Why do some people treated for psoriatic arthritis stop responding to their treatment Find out next. Study Confirms High Prevalence of ADA in AdalimumabTreated Psoriasis Dr. Graeme M. Lipper, writing in Medscape described a recent study that might shed light on why some treatments for psoriatic arthritis may fail over time. Menting, Lumig, DeVries and colleagues published the results of a recent study entitled Extent and Consequences of Antibody Formation Against Adalimumab in Patients With Psoriasis OneYear Followup Adalimumab, a humanized monoclonal antibody IgG1 that binds to and inactivates the proinflammatory.
Cytokine tumor necrosis factor alpha, is a highly effective treatment for moderate to severe psoriatic arthritis. Unfortunately, this drug may induce antidrug antibodies ADAs in almost one half of patients taking adalimumab longterm, and prior studies show that ADAs contribute to disease relapse and waning therapeutic response to adalimumab and other biologic therapies. In their study they found that 49 of patients developed ADAs, with the vast majority 90 forming antibody titers within the first 24 weeks of therapy. Comment Interesting and answers a lot of questions about failing therapy.